| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 08/11/2009 | US7572920 Benzimidazole derivative and use as a II receptor antagonist |
| 08/11/2009 | US7572910 Heteroaromatic substituted sulfonyl or sulfoxide or thio-pyridazinone derivatives, useful for treating diabetic complications and cardiovascular disorders; eg 3-Methoxy-6-(5-chloro-3-methyl-benzofuran-2-sulfenyl)-pyridazine |
| 08/11/2009 | US7572900 Expression vector comprising breast cancer gene (BCL-2) nucleotide sequences for use as tool in treatment, diagnosis and prevention of cell proliferative disorders |
| 08/11/2009 | US7572888 Fusion protein comprising arrestin and green fluorescent protein for use in identifying ligands for g-protein coupled receptors |
| 08/11/2009 | US7572886 Death associated proteins, and THAP1 and PAR4 pathways in apoptosis control |
| 08/11/2009 | US7572828 Identification of anti-HIV compounds inhibiting virus assembly and binding of nucleocapsid protein to nucleic acid |
| 08/11/2009 | US7572800 Administering anti-hepatitis B virus agents in combination or alternation such asbeta-2-hydroxymethyl-5-(5-fluorocytosin-1-yl-1,3-oxathiolane or a salt and one another antihepatitis B agent |
| 08/11/2009 | US7572782 Use of targeted oxidative therapeutic formulation in bone regeneration |
| 08/11/2009 | US7572779 Improved oral bioavailability of 17 beta-estradiol by adminstering the lower alkanoate; contraceptives, hormone replacement therapy |
| 08/11/2009 | US7572770 Use of an interleukin 1 receptor antagonist and/or pyrrolidinedithiocarbamate for the treatment or prophylaxis of type 2 diabetes |
| 08/11/2009 | US7572768 Methods for identifying compounds for regulating muscle mass or function using corticotropin releasing factor receptors |
| 08/11/2009 | US7572762 Materials and methods relating to the induction of apoptosis in target cells |
| 08/11/2009 | US7572613 Drug delivery system for accelerated subcutaneous absorption |
| 08/11/2009 | US7572466 Oral immunology using plant product containing a non-enteric pathogen antigen |
| 08/11/2009 | US7572446 Antagonists of HMG1 for treating inflammatory conditions |
| 08/11/2009 | US7572442 Selected antibody compositions for binding to aminophospholipids |
| 08/11/2009 | US7572438 Mutant having uracil phosphoribosyl transferase activity |
| 08/11/2009 | US7572437 Long acting human interferon analogs |
| 08/11/2009 | US7572436 Thionin as an antineoplastic and immunostimulant |
| 08/11/2009 | CA2548834C Tamper resistant co-extruded dosage form containing an active agent and an adverse agent and process of making same |
| 08/11/2009 | CA2476520C Long acting parasiticidal composition containing a salicylanilide compound, a polymeric species and at least one other anti-parasitic compound |
| 08/11/2009 | CA2470581C Antidiabetic formulation and method |
| 08/11/2009 | CA2448825C Pharmaceutical compositions of adsorbates of amorphous drug |
| 08/11/2009 | CA2392013C Analgesic compositions containing buprenorphine in combination with naloxone, naltrexone or nalmefene |
| 08/11/2009 | CA2375378C Antilipemic combinations comprising hmg-coa reductase inhibitors and carnitines |
| 08/11/2009 | CA2358361C Stable compositions for parenteral administration and their use |
| 08/11/2009 | CA2335012C Pharmaceutical compositions for the prevention and treatment of central nervous system disorders |
| 08/11/2009 | CA2271248C Use of a notch ligand in immunotherapy |
| 08/11/2009 | CA2258503C Lectin compositions and uses thereof |
| 08/07/2009 | CA2643611A1 Biomarkers for head-and-neck cancers and precancers |
| 08/06/2009 | WO2009096581A1 Membrane fusion inhibitor |
| 08/06/2009 | WO2009096564A1 Prophylactic or therapeutic agent for attention deficit/hyperactivity disorder |
| 08/06/2009 | WO2009096196A1 Method for determination of sensitivity to anti-cancer agent |
| 08/06/2009 | WO2009096189A1 Marker for determination of sensitivity to anti-cancer agent |
| 08/06/2009 | WO2009095454A2 Method for the identification of patients in need of therapy having minor cognitive disorders and the treatment of such patients |
| 08/06/2009 | WO2009095437A1 Use of eicosapentaenoic acid and/or docosahexahenoic acid in women with endometriosis |
| 08/06/2009 | WO2009075841A3 Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of antecedent hematologic disorders |
| 08/06/2009 | WO2009073146A3 Use of immunomodulatory compounds for the treatment of transverse myelitis, multiple sclerosis, and other disorders |
| 08/06/2009 | WO2009071094A3 Combination treatment of ischemic effects |
| 08/06/2009 | WO2008132500A3 Chkl inhibitors with b cell depleting antibodies for the treatment of hematologic malignancies |
| 08/06/2009 | WO2008124081A3 Rapid dissolution of combination products |
| 08/06/2009 | WO2008116890A3 Pharmaceutical compositions comprising flibanserin and a further agent in the treatment of sexual disorders |
| 08/06/2009 | WO2008100450A4 Therapeutic effects of bryostatins, bryologs, and other related substances on ischemia/stroke-induced memory impairment and brain injury |
| 08/06/2009 | WO2002102301A3 Substituted indole-2-carboxylic acid benzylidene-hydrazides and analogs as activators of caspases and inducers of apoptosis and the use thereof |
| 08/06/2009 | US20090197949 Antitumor methods and compositions comprising sesquiterpene derivatives |
| 08/06/2009 | US20090197887 Piperazinylpiperidine derivatives as chemokine receptor antagonists |
| 08/06/2009 | US20090197836 Combination of FBPase Inhibitors and Antidiabetic Agents Useful for the Treatment of Diabetes |
| 08/06/2009 | US20090197813 Methods for treating FSH related conditions with GnRH antagonists |
| 08/06/2009 | US20090197803 METHODS AND COMPOSITIONS FOR MODULATING T HELPER (Th) CELL DEVELOPMENT AND FUNCTION |
| 08/06/2009 | US20090196871 Use of 4-pyridylmethylphthalazines for cancer treatment |
| 08/06/2009 | DE102008007218A1 Preventive treatment of patients with mild cognitive disorders, which based on increase of circulation-relevant peptide-biomarker measurable in circulation, with medicament comprising e.g. angiotensin converting enzyme-inhibitor |
| 08/06/2009 | CA2713598A1 Prophylactic or therapeutic agent for attention deficit/hyperactivity disorder |
| 08/06/2009 | CA2713296A1 Method for determination of sensitivity to anti-cancer agent |
| 08/06/2009 | CA2712966A1 Marker for determination of sensitivity to anti-cancer agent |
| 08/06/2009 | CA2712856A1 Use of eicosapentaenoic acid and/or docosahexaenoic acid in women with endometriosis |
| 08/05/2009 | EP2085478A1 A long QT syndrome gene which encodes KVLQT1 and its association with minK |
| 08/05/2009 | EP2085109A2 Transdermal drug delivery devices having coated microprotrusions |
| 08/05/2009 | EP2085095A1 Combination of an anti-EDb fibronectin antibody-IL-2 fusion protein, and a molecule binding to B cells, B cell progenitors and/or their cancerous counterpart |
| 08/05/2009 | EP2085094A2 Application of aminopeptidases inhibitors and pharmaceutical preparations containing same |
| 08/05/2009 | EP2085087A1 Prodrugs of gaba analogs, compositions and uses thereof |
| 08/05/2009 | EP2085085A1 The uses of the carboxy-amido-triazole compounds and salts thereof |
| 08/05/2009 | EP2083921A2 Pharmaceutical combinations of a nicotine receptor modulator and a cognitive enhancer |
| 08/05/2009 | EP2083876A2 Methods of wound care and treatment |
| 08/05/2009 | EP2083866A2 Lipidized interferon and uses thereof |
| 08/05/2009 | EP2083863A1 Use of tgf-beta antagonists to treat infants at risk of developing bronchopulmonary dysplasia |
| 08/05/2009 | EP2083830A1 Improved methods of using phosphoantigen for the treatment of cancer |
| 08/05/2009 | EP2083808A1 Use of buprenorphine or n-alkylated derivatives thereof for wound healing |
| 08/05/2009 | EP2083796A2 Enzyme inhibition using nanoparticles |
| 08/05/2009 | EP2012801A4 Gemcitabine combination therapy |
| 08/05/2009 | EP1680106B1 Combination treatment of obesity involving 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity and lipase inhibitors |
| 08/05/2009 | EP1622586B1 Process for preparing tannate tablet capsule or other solid dosage forms |
| 08/05/2009 | EP1509506B1 Pyridazine derivatives |
| 08/05/2009 | EP1430085B1 Leukocyte inactivation module |
| 08/05/2009 | EP1430040B1 Benzothiazepine derivatives |
| 08/05/2009 | EP1401825B1 Thiophene derivatives as antiviral agents for flavivirus infection |
| 08/05/2009 | EP1383731B1 Biaryl compounds as serine protease inhibitors |
| 08/05/2009 | EP1253939B1 In vivo ctl elicitation by heat shock protein fusion proteins maps to a discrete atp binding domain and is cd4+ t cell-independent |
| 08/05/2009 | EP1179086B1 Methods of identifying therapeutic compounds in a genetically defined setting |
| 08/05/2009 | EP1087756B1 Particulate acellular tissue matrix |
| 08/05/2009 | EP0819004B1 Pharmaceutical composition containing proton pump inhibitors |
| 08/05/2009 | EP0813424B2 Oral pharmaceutical dosage forms comprising a proton pump inhibitor and an antacid agent or alginate |
| 08/05/2009 | CN101500611A Combination of a cholinesterase inhibitor and a compound with 5-HT6 receptor affinity |
| 08/05/2009 | CN101500610A Anti-obesity agent and use thereof |
| 08/05/2009 | CN101500609A Hematopoietic stem cell proliferation promoter |
| 08/05/2009 | CN101500608A Preventive or remedy for inflammatory disease |
| 08/05/2009 | CN101496827A Application of pumpkin protein in preparing medicament for treating chronic myeloid leukemia |
| 08/05/2009 | CN100523215C RNA interference mediating small RNA molecules |
| 08/05/2009 | CN100523198C Method for detection of leptin receptor ligands |
| 08/05/2009 | CN100522997C Method and composition for treating cardiovascular diseases by employing neuroregulation protein |
| 08/05/2009 | CN100522991C Peptidomimetic protease inhibitors |
| 08/05/2009 | CN100522967C Phosphorus-containing compounds & uses thereof |
| 08/05/2009 | CN100522946C Stabilization of hypoxia inducible factor (HIF) alpha |
| 08/05/2009 | CN100522945C Substituted 2-thio-3,5-dicyano-4-phenyl-6-aminopyridines and use thereof |
| 08/05/2009 | CN100522937C Anthranilic acid amides, method for the production thereof, their use as antiarrhythmia agents, and pharmaceutical preparations thereof |
| 08/05/2009 | CN100522245C Compositions for transmucosal drug delivery and cryoprotection |
| 08/05/2009 | CN100522166C (1-4-piperidinyl) benzimidazole derivatives useful as histamine H3 antagonists |
| 08/05/2009 | CN100522159C The use of substituted azetidinone compounds for the treatment of sitosterolemia |
| 08/05/2009 | CN100522157C Treatment of diseases involving defective gap junctional communication |
| 08/05/2009 | CN100522154C Use of isothiocyanates compound for treatment of helicobacter |
| 08/04/2009 | US7569592 Heteroaryl substituted pyrazole modulators of metabotropic glutamate receptor-5 |